Abstract
Abstract Immune checkpoint blockade has changed the treatment landscape for metastatic urothelial cancer. However, the role of PD-1/PD-L1 blockade in the treatment of metastatic diseaes continues to rapidly evolve since the initialy regulatory approval of these therapies in 2016. Defining biomarkers with sufficient predictive ability to establish clinical utility for selection of patients who can receive single agent PD-1/PD-L1 blockade has been challenging. However, combination regimens with either cisplatin-based chemotherapy or enfortumab vedotin has for the first time in decades improved survival compared with platinum-based chemotherapy alone. Refining the use of such combination regimens requires a better understanding of the potential immunomodulatory effects of cytotoxic therapies. Citation Format: Matthew D. Galsky. The evolving role of immune-based treatment strategies in metastatic urothelial cancer [abstract]. In: Proceedings of the AACR Special Conference on Bladder Cancer: Transforming the Field; 2024 May 17-20; Charlotte, NC. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(10_Suppl):Abstract nr IA016.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
